Cytokinetics lead product
WebFeb 2, 2024 · Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing muscle activators and inhibitors. Investors … WebCytokinetics, Inc. is a publicly traded biopharmaceutical company based in South San Francisco, California, that develops muscle activators and muscle inhibitors as potential treatments for people with diseases characterized by …
Cytokinetics lead product
Did you know?
WebHeadquarters United States of America. Address ., 280 East Grand Avenue, South San Francisco, California, 94080. Website cytokinetics.com. Telephone 1 650 6243000. No of Employees 253. Industry Pharmaceuticals and Healthcare. Ticker Symbol & Exchange CYTK (NASD) Revenue (2024) $70.4M 26.2% (2024 vs 2024) EPS XXX. WebCytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments …
WebFeb 2, 2024 · Cytokinetics’ lead drug candidate is tirasemtiv, a fast skeletal muscle troponin activator. Tirasemtiv is the subject of VITALITY-ALS, an international Phase 3 clinical trial in patients with ALS. Tirasemtiv has been granted orphan drug designation and fast track status by the U.S. Food and Drug Administration and orphan medicinal … WebCytokinetics is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential ...
WebMar 4, 2024 · March 4, 2024, 10:00 AM · 10 min read Cytokinetics, Incorporated Treatment with Aficamten Resulted in Significant Improvements in Heart Failure Symptoms and Cardiac Biomarkers in Patients with... WebFeb 1, 2024 · Cytokinetics continues its over 20-year history of pioneering innovation in muscle biology and related pharmacology focused to diseases of muscle dysfunction and …
WebFeb 17, 2024 · Cytokinetics’ lead drug candidate is tirasemtiv, a fast skeletal muscle activator, for the potential treatment of ALS. Tirasemtiv has been granted orphan drug designation and fast track status by the U.S. Food and Drug Administration and orphan medicinal product designation by the European Medicines Agency for the potential …
WebJul 27, 2024 · Cytokinetics’ lead drug candidate is tirasemtiv, a fast skeletal muscle troponin activator, for the potential treatment of ALS. Tirasemtiv has been granted orphan drug designation and fast track … csww incWebOct 20, 2014 · SOUTH SAN FRANCISCO, CA, October 20, 2014 - Cytokinetics, Incorporated ( CYTK) provided a program update today relating to tirasemtiv, the company`s lead drug candidate from its skeletal muscle... earn money as a student philippinesWebCytokinetics' cardiovascular disease program is focused to cardiac myosin, a motor protein essential to cardiac muscle contraction. Cytokinetics' lead compound from this program, CK-1827452, a novel small molecule cardiac myosin activator, entered Phase II clinical trials for the treatment of heart failure in 2007. csw wine certificationWebFeb 2, 2024 · Cytokinetics has agreed to sell 4.5% of its potential royalties from partner Amgen on potential global sales of omecamtiv mecarbil — a novel therapy aimed at … csw wheelsWebJul 19, 2024 · Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in … earn money as a writerWebApr 6, 2024 · Its lead drug candidate from its cardiac muscle contractility program, omecamtiv mecarbil, is in Phase II clinical development for the potential treatment of heart failure. The company also holds an exclusive license worldwide to develop and commercialize omecamtiv mecarbil and related compounds, subject to Cytokinetics' … csww inc great fallsWebApr 10, 2024 · SOUTH SAN FRANCISCO, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to participate in a fireside chat at the 22 nd Annual Needham Virtual Healthcare Conference on Monday, April 17, 2024 at 10:00 … csww inc north 40